4.5 Article

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis

Journal

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 63, Issue 2, Pages 178-193

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12016-021-08911-z

Keywords

Autoantibody; Autoimmune hepatitis; Autoimmune myositis; Interstitial lung disease; Ro52; Sjogren's syndrome; Systemic lupus erythematosus; Systemic sclerosis

Ask authors/readers for more resources

This review summarizes the research progress on the autoantibody to Ro52/TRIM21 in SLE and SjS patients over the past 30 years. The anti-Ro52 has been found to be associated with various diseases, including neonatal lupus erythematosus, subacute cutaneous lupus erythematosus, interstitial lung disease, and certain cancers, suggesting its potential diagnostic and pathogenic roles in these conditions.
This review highlights the 30 plus years research progress since the discovery of autoantibody to Ro52/TRIM21 in patients with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SjS). After the initial expression cloning of the Ro52 cDNA, it has taken many years to the current understanding in the interesting biological function of Ro52 as an E3 ubiquitin ligase and its role in innate immune clearance of intracellular IgG-bound complex. Early observations show that anti-Ro52, mostly associated with anti-SS-A/Ro60 and/or anti-SS-B/La, is commonly found in SLE (40-70%), SjS (70-90%), neonatal lupus erythematosus (NLE, 75-90%), and subacute cutaneous lupus erythematosus (50-60%). Anti-Ro52 has long been postulated to play a direct pathogenic role in congenital heart block in NLE as well as in the QT interval prolongation in some adults. The widespread availability of the anti-Ro52 assay has led to the detection of anti-Ro52 in other diseases including autoimmune hepatitis (20-40%), systemic sclerosis (10-30%), and autoimmune myositis (20-40%). More than ten studies have pointed to an association of anti-Ro52 with interstitial lung disease and, more importantly, correlating with poor outcome and worse survival. Other studies are implicating an interesting role for anti-Ro52 in the diagnosis of certain cancers. Future studies are needed to examine the mechanism in the pathogenesis of anti-Ro52 and carefully documenting its causal relationships in different disease conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available